Full Logo - OKYO .jpg
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
02 avr. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Full Logo - OKYO .jpg
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
22 mars 2024 07h00 HE | OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
Full Logo - OKYO .jpg
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
21 mars 2024 07h00 HE | OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
Full Logo - OKYO .jpg
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20 mars 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Global Refractive Surgery Devices Market
Refractive Surgery Devices Market to Reach USD 393.12 Million by 2030 - An Insightful Analysis of Industry Growth, Trends, and Forecasts
22 févr. 2024 04h09 HE | Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Refractive Surgery Devices Market by Product Type (Aberrometers, Microkeratome, Ophthalmic Laser), Application (Astigmatism, Dry Eyes,...
Straits Research Pvt Ltd
Global Ophthalmic Drugs Market Size is Estimated to Reach USD 62.55 billion by 2030, Growing at a CAGR of 7.4%: Straits Research
21 févr. 2024 10h20 HE | Straits Research
New York, United States, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Anti-infectives in a product designed specifically to be injected into or applied to the eye or eyes are known as ophthalmic...
Global OTC Dry Eye Drops Market
OTC Dry Eye Drops Market to Surge to USD 8.40 Billion by 2034, Thanks to Rising Prevalence of Dry Eye Syndrome and Technological Advancements
05 févr. 2024 04h36 HE | Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Global OTC Dry Eye Drops Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With dry eye...
Full Logo - OKYO .jpg
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
31 janv. 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
22157.jpg
Global Artificial Tear Market Forecast to 2030 Featuring Analysis of J&J Vision Care, Allergan, Alcon, Bausch & Lomb, Santen, URSAPHARM Arzneimittel, and ROHTO Pharmaceutical
24 janv. 2024 05h07 HE | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Artificial Tear Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. With...
Full Logo - OKYO .jpg
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
08 janv. 2024 07h00 HE | OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...